TuBerculosis Viability Interregional Study and Agreement on Biological Tests

Tuberculosis, Pulmonary Clinical Trial

— TBVISA  

Official title:

Multicenter Prospective Evaluation of Rapid Viability Tests for Mycobacterium Tuberculosis to Improve the Follow-up of Tuberculosis Patients and Guide Isolation Measures

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04968886
• Other study ID #: APHP180578
• Status: Not yet recruiting
• Start date: September 2022
• Est. completion date: December 2023

Study information

• Verified date: June 2022
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Benjamin WYPLOSZ, Ph
• Phone: 01 45 21 74 25
• Email: benjamin.wyplosz[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of the present study is to confirm in a multicentric study the utility of our viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help physicians to discontinue isolation measures in hospital setting.

Description:

When patients with pulmonary tuberculosis (TB) are hospitalized for diagnosis and treatment, isolation measures are mandatory in order to prevent transmission. Recommendations are to maintain isolation until patients are no more infectious, which is ascertained when cultures of respiratory specimens become negative (culture conversion). After administration of antibiotics, the average time to culture conversion is one month for patients with drug-susceptible TB, but 5%-30% cases require more than two months and up to 6 months can be required for multiresistant (MDR)-TB.

Microscopic examination of bacilli in respiratory samples is mainly used as a surrogate marker but because bacilli staining does not differentiate alive from dead bacilli, the interpretation of positive smears is misleading. After 1-2 months of treatment, bacilli can be considered dead while they are still alive and isolation measures are thus erroneously discontinued. Conversely, bacilli can be considered viable while they have already been killed by the treatment and patients kept inadequately in isolation.

To overcome the misleading results, attempts have been made to develop viability biomarkers for Mycobacterium tuberculosis (Mtb), the agent of tuberculosis. Studies using RNA or DNA gave convincing results but their cost is not affordable in most part of the world. Those using fluorescein probes are easiest but studies have shown either conflicting results, or have been evaluated only for a short period of time after initiation of therapy.

Thus, we evaluated a fluorescent staining able to differentiate dead bacilli from alive, which was previously used for detection of industrial environmental pathogens - the Live/Dead® BacLight™ Bacterial viability test (Invitrogen, Biocentric, France). Briefly, the test permits to visualize the bacteria using SYTO-9 and propidiumiodide (PI) fluorescent dyes, which both bind to DNA but penetrate specifically cytoplasmic membrane: SYTO-9 penetrates all bacilli, either viable or not, whereas the PI penetrates only in cells with damaged membrane. Consequently, the viable bacteria are impermeable to PI and only fluoresced due to SYTO-9 appearing green under the fluorescent microscope, whereas dead bacteria are marked by both fluorescent dyes and appear red.

We firstly adapted the kit to mycobacteriology and assessed, in in vitro experiments, the concordance of the test with the culture results. Then, we showed in an observational prospective study its accurateness to predict culture results in patients undergoing antituberculous therapy: the viability test correctly predicted all culture-positive samples in the first two months after treatment.

The objective of the present study is to confirm in a multicentric study the utility of our viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help physicians to discontinue isolation measures in hospital setting.

Since the test is quick (less than 1 h for the test versus a median of 23 days for culture) and easy to perform, it would be useful to help physicians to maintain isolation in clinical settings while avoiding unnecessary cultures. Since the test is also cheap (<1 € for reagents) this issue could be particularly valuable in countries with limited resources and where cultures are unavailable.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 104
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age from 18 years old

• Patient put on anti-tuberculosis treatment for pulmonary tuberculosis with at least one positive ME

• Information given on the study and the right to oppose

Exclusion Criteria:

• Refusal of participation

• People unable to understand the information, In accordance with article 11218 of the public health code,

• people not affiliated with Health Insurance,

• pregnant or breastfeeding women patients under legal protection can be included in a non-interventional study (type 3).

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Diagnostic Test:
• Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
Diagnostic Test: viability test on sputum and comparision with culture results (reference test)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Result of the viability test (positive or negative) compared to culture results (reference test). - The reference test will be considered as positive (C+) if Mtb are grown on solid or liquid media et negative (C-) if the cultures remain sterile after 42	The culture will be judged positive in case of isolation of tubercle bacilli in solid or liquid medium and will be judged negative if the culture is sterile after 42 days of incubation in liquid medium and 60 days in solid medium. If the culture is contaminated with bacteria other than tubercle bacilli, it will be considered uninterpretable.; - The microscopic viability test will be judged positive in the event of observation of at least 1 bacillus per slide is stained with Syto9 in fluorescent green per slide on microscopic examination of the smear and will be judged negative if no bacillus fluoresces in green .; Each test will be interpreted blind to the results of the other and the results of the TVmol. the diagnostic indices of the microscopic viability test will be calculated	12 months
Secondary	Evaluate the diagnostic performance of the molecular test for the viability of tuberculosis bacilli	Using real-time Polymerase Chain Reaction amplification in comparison with the bacterial culture (reference test).	12 months
Secondary	Study the correlation between the quantitative results of viability tests and the quantitative results of the culture	Microscopic viability test expressed as the number of fluorescent green bacilli, and culture results expressed in number of colonies for culture in solid medium and Molecular viability test expressed in number of amplification cycles to reach the positivity threshold and in molecular concentration of the target gene and the culture results expressed	12 months
Secondary	Evaluate the potential benefit of viability tests for the patient and the hospital over the duration of isolation and the time to discharge from hospital	Evaluate the potential benefit of viability tests for the patient and the hospital over the duration of isolation and the time to discharge from hospital	12 months
Secondary	Describe the cohort of patients hospitalized for pulmonary tuberculosis with positive microscopic examination in the 10 participating centers	Describe the cohort of patients hospitalized for pulmonary tuberculosis with positive microscopic examination in the 10 participating centers	12 months